Sponsor

Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

The Netherlands Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands

About the sponsor

HOVON supports clinical research in newly diagnosed and relapsed acute myeloid leukemia, including molecularly defined disease with NPM1, IDH1, IDH2, and FLT3 alterations. Its portfolio also includes myelodysplastic syndrome and MDS-EB2, with interest in treatment-resistant and unfit patient populations.

Targeted therapy in molecularly defined AML
Combination regimens for newly diagnosed disease
Maintenance strategies in AML and MDS

Research activity in this area spans intensive and non-intensive treatment settings, with attention to remission depth, survival outcomes, and disease control in older or medically complex patients.

About Specializations

Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting runs clinical trials in conditions such as Chronic lymphocytic leukaemia, Acute myeloid leukaemia, Diffuse large B-cell lymphoma, B-cell small lymphocytic lymphoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

29 clinical trials

Chronic lymphocytic leukaemia+1

Recruiting

Study of pirtobrutinib plus epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

Registered drugNo placebo

Study of pirtobrutinib plus epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Chronic lymphocytic leukaemia+2

Recruiting

Rituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

Rituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Venetoclax
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Waldenstrom's macroglobulinaemia+2

Recruiting

A study to evaluate the effectiveness of epcoritamab in patients with Waldenström's macroglobulinemia that has returned or has not responded to previous treatments.

InvestigationalNo placebo

A study to evaluate the effectiveness of epcoritamab in patients with Waldenström's macroglobulinemia that has returned or has not responded to previous treatments.

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Acute myeloid leukaemia

Recruiting

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational

Austria

Participants:18–64 years · 65+ years
Substances:Bleximenib
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Study on Golcadomide for Patients with Relapsed or Refractory Large B-Cell Lymphoma in the Brain

Recruiting

InvestigationalNo placebo

Study on Golcadomide for Patients with Relapsed or Refractory Large B-Cell Lymphoma in the Brain

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Golcadomide
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug